Treatment response heterogeneity in asthma: the role of genetic variation

Expert Review of Respiratory Medicine

Volumn 12, Issue 1, 2018, Pages 55-65

  Vijverberg, Susanne J H ^a   Farzan, Niloufar ^a   Slob, Elise M A ^a   Neerincx, Anne H ^a   Maitland van der Zee, Anke H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Asthma; corticosteroids; genetics; leukotriene antagonists; pharmacogenetics; pharmacogenomics; 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ADRB2 PROTEIN, HUMAN; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR;

ASTHMA; CORTICOSTEROID THERAPY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENETIC VARIATION; HUMAN; REVIEW; TREATMENT RESPONSE; GENETICS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PHARMACOGENETICS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; GENETIC VARIATION; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 85038261735     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2018.1403318     Document Type: Review

References (74)

1. Global INitiative for Asthma (GINA) Report. Global strategy for asthma management and prevention global strategy for asthma management and prevention. [Updated 2017; cited 2017 Nov Sep1]. Available from: http://ginasthma.org/gina-reports/
2. Gibson GJ, Loddenkemper R, Sibille Y, et al. The European lung white book. Sheffield: European Respiratory Society; 2013.
3. British Thoracic Society. British guideline on the management of asthma. [Edition 2016; cited 2017 Sep14]. Available from: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/
4. Hilvering B, Pavord ID., What goes up must come down: biomarkers and novel biologicals in severe asthma. Clin Exp Allergy. 2015;45(7):1162–1169.
5. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117(1):45–52.
6. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–242.
7. Hersh CP, Soto-Quirós ME, Avila L, et al. Genome-wide linkage analysis of pulmonary function in families of children with asthma in Costa Rica. Thorax. 2007;62(3):224–230.
8. McGeachie MJ, Stahl EA, Himes BE, et al. Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes. Pharmacogenet Genomics. 2013;23(6):324–328.
9. Lima JJ., Do genetic polymorphisms alter patient response to inhaled bronchodilators? Expert Opin Drug Metab Toxicol. 2014;10(9):1231–1240.
10. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55(9):762–767.
11. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 1998;11(3):589–593.
12. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162(1):75–80.
13. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505–1512.
14. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012;8(7):e1002824.
15. Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J. 2014;14(1):41–47.
16. Israel E, Lasky-Su J, Markezich A, et al. Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3. Am J Respir Crit Care Med. 2015;191(5):530–537.
17. Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol. 2014;133(2):370–378.
18. Padhukasahasram B, Yang JJ, Levin AM, et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J. 2014;14(4):365–371.
19. Brehm JM, Man Tse S, Croteau-Chonka DC, et al. A genome-wide association study of post-bronchodilator lung function in children with asthma. Am J Respir Crit Care Med. 2015;192(5):634–637.
20. Remington TL, Digiovine B. Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med. 2005;11(1):74–78.
21. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118(4):809–816.
22. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370(9605):2118–2125.
23. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374(9703):1754–1764.
24. Lipworth BJ, Basu K, Donald HP, et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clinical Science. 2013;124(8):521–528.
25. Turner S, Francis B, Vijverberg S, et al. Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: a meta-analysis stratified by treatment. J Allergy Clin Immunol. 2016;138(1):107–113.e105.
26. Vijverberg SJ, Pijnenburg MW, Hövels AM, et al. The need for precision medicine clinical trials in childhood asthma: rationale and design of the PUFFIN trial. Pharmacogenomics. 2017;18(4):393–401.
27. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014;2(3):204–213.
28. Litonjua AA, Lasky-Su J, Schneiter K, et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med. 2008;178(7):688–694.
29. Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med. 2011;183(4):449–454.
30. Park HW, Dahlin A, Tse S, et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014;133(3):664–669.e665.
31. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365(13):1173–1183.
32. Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012;185(12):1286–1291.
33. Dahlin A, Denny J, Roden DM, et al. CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids. Immun Inflamm Dis. 2015;3(4):350–359.
34. Park TJ, Park JS, Cheong HS, et al. Genome-wide association study identifies ALLC polymorphisms correlated with FEV₁ change by corticosteroid. Clin Chim Acta. 2014;436:20–26.
35. Wang Y, Tong C, Wang Z, et al. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J. 2015;15(5):422–429.
36. Mosteller M, Hosking L, Murphy K, et al. No evidence of large genetic effects on steroid response in asthma patients. J Allergy Clin Immunol. 2017;139(3):797–803.e7.
37. Li M, Reilly MP, Rader DJ, et al. Correcting population stratification in genetic association studies using a phylogenetic approach. Bioinformatics. 2010;26(6):798–806.
38. Leusink M, Vijverberg SJ, Koenderman L, et al. Genetic variation in uncontrolled childhood asthma despite ICS treatment. Pharmacogenomics J. 2016;16(2):158–163.
39. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007;448(7152):470–473.
40. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211–1221.
41. Farzan N, Vijverberg SJ, Arets HG, et al. Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. Clin Exp Allergy. 2017;47(2):271–293.
42. Hosking L, Bleecker E, Ghosh S, et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol. 2014;133(2):587–589.
43. Izuhara Y, Matsumoto H, Kanemitsu Y, et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy. 2014;69(5):668–673.
44. Vijverberg SJ, Tavendale R, Leusink M, et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics. 2014;15(6):799–806.
45. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13(13):1353–1359.
46. Mougey EB, Chen C, Tantisira KG, et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2013;13(3):242–250.
47. Rogers AJ, Tantisira KG, Fuhlbrigge AL, et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics. 2009;10(8):1231–1242.
48. Dijkstra A, Koppelman GH, Vonk JM, et al. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol. 2008;121(6):1510–1513.
49. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol. 2007;120(6):1285–1291.
50. Koster ES, Maitland-van der Zee A-H, Tavendale R, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy. 2011;66(12):1546–1552.
51. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130(6):487–495.
52. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110(6):847–854.
53. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19(2):129–138.
54. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17(3):189–196.
55. Drazen JM, Yandava CN, Dubé L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22(2):168–170.
56. Telleria JJ, Blanco-Quiros A, Varillas D, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008;102(6):857–861.
57. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173(4):379–385.
58. Fowler SJ, Hall IP, Wilson AM, et al. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol. 2002;58(3):187–190.
59. Mougey E, Lang JE, Allayee H, et al. ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. Clin Exp Allergy. 2013;43(5):512–520.
60. Tantisira KG, Lima J, Sylvia J, et al. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009;19(3):244–247.
61. Kotani H, Kishi R, Mouri A, et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. J Clin Pharm Ther. 2012;37(1):112–116.
62. Dahlin A, Litonjua A, Lima JJ, et al. Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PLoS One. 2015;10(6):e0129385.
63. Dahlin A, Litonjua A, Irvin CG, et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J. 2016;16(2):151–157.
64. Drazen JM, Silverman EK, Lee TH, Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4):1054–1070.
65. Farzan N, Vijverberg SJ, Andiappan AK, et al. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics. 2017;18(10):931–943.
66. Almoguera B, Vazquez L, Mentch F, et al. Identification of four novel loci in asthma in European American and African American populations. Am J Respir Crit Care Med. 2017;195(4):456–463.
67. Ober C. Asthma genetics in the post-GWAS era. Ann Am Thorac Soc. 2016;13 Suppl 1:S85–90.
68. Tonk ECM, Gurwitz D, Maitland-van der Zee A-H, et al. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017;17(4):386–392.
69. Forno E, Sordillo J, Brehm J, et al. Genome-wide interaction study of dust mite allergen on lung function in children with asthma. J Allergy Clin Immunol. 2017;140(4):996–1003.e7.
70. Yang IV, Pedersen BS, Liu AH, et al. The nasal methylome and childhood atopic asthma. J Allergy Clin Immunol. 2014;133(2):587–589.
71. Wysocki K, Conley Y, Wenzel S. Epigenome variation in severe asthma. Biol Res Nurs. 2015;17(3):263–269.
72. Brinkman P, Van de Pol MA, Gerritsen MG, et al. Exhaled breath profiles in the monitoring of loss of control and clinical recovery in asthma. Clin Exp Allergy. 2017;47(9):1159–1169.
73. Van der Schee MP, Palmay R, Cowan JO, et al. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013;43(11):1217–1225.
74. Gustafsson M, Nestor CE, Zhang H, et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med. 2014;6(10):82.